Lead Product(s) : 5-Methyltetrazole
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : $261.0 million
Deal Type : Collaboration
Details : A2a/A2b antagonist candidate, M1069, a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectable solid tumors.
Brand Name : M1069
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2022
Lead Product(s) : 5-Methyltetrazole
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : $261.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
